Like semaglutide and tirzepatide, it is a glucagon-like peptide-1 (GLP-1) agonist, meaning it acts on GLP-1 receptors just like the natural GLP-1 hormone in your body
PubChem, US National Library of Medicine
Pricing: View pricing and shop directly through the Prestige App

Markers community sources associate with a working protocol: Sleep quality improved within the first 1-2 weeks IGF-1 increased 20-40%+ from baseline at 4-6 week bloodwork Gradual improvements in recovery, skin quality, or body composition by weeks 6-8 Mild, transient side effects (slight water retention, occasional joint stiffness) that resolve Patterns community sources describe before discontinuing: No sleep improvement after 2 weeks community sources describe verifying fasted injection timing and peptide source quality IGF-1 unchanged at 4-6 weeks community protocols describe increasing to twice-daily dosing (300 mcg AM + PM) or evaluating peptide authenticity Persistent water retention or joint pain beyond week 3 community sources interpret this as a dose running too high and describe reducing to 200 mcg Signals community and clinical sources associate with stopping: Persistent numbness or tingling in extremities (potential carpal tunnel from excessive GH) Blood glucose consistently elevated on follow-up labs Any signs of abnormal growth or tissue changes documented guidance is to discontinue and consult a physician For detailed protocol parameters, see the ipamorelin dosing guide

Furthermore, luciferase activity was significantly reduced within the 100 to +100 bp region upstream of the DEPTOR promoter, indicating the presence of an ILF3 binding site in this region (Fig
It's your roadmap to knowing what's covered and what's not